CD8A and neoplasm: Recent studies have demonstrated that progenitor-exhausted CD8+ T cells expressing transcription factor TCF1 (T cell factor 1, encoded by Tcf7), are key mediators of anti-PD-1 therapy to inhibit tumor progression7,8.